Invesco Dynamic Pharmaceuticals ETF (PJP) has seen unusual trading volume, which is 21× higher than its average daily volume.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The ETF’s top positions are seeing active analyst coverage, with Pfizer, Merck, Johnson & Johnson, Amgen, AbbVie, Eli Lilly, and Abbott Laboratories all highlighted in fresh research. RBC Capital reaffirmed a Sell rating on Pfizer, while BMO and other firms maintained bullish views on Merck, and Guggenheim reiterated a Buy on Johnson & Johnson with double‑digit upside implied. AbbVie and Eli Lilly drew particularly positive attention, with multiple analysts maintaining or initiating Buy ratings and issuing aggressive price targets as AbbVie’s immunology and neuroscience franchises and Eli Lilly’s obesity and oncology pipelines remain key drivers, while Abbott Laboratories also retained a Strong Buy consensus despite a Hold rating and modestly higher price target from Mizuho.